Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.

doi:10.1016/j.gastrohep.2022.12.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.

Gastroenterologia y hepatologia - 1 Oct 2023

Martínez-Campreciós Joan, Riveiro-Barciela Mar, Muñoz-Gómez Raquel, Londoño María-Carlota, Roget Mercé, Serra Miguel Ángel, Escudero-García Desamparados, Purchades Laura, Rodríguez Manuel, Losa-García Juan E, Gutiérrez María L, Carmona Isabel, García-Samaniego Javier, Morano Luís, Martín-Granizo Ignacio, Montero-Alonso Marta, Prieto Martín, Delgado Manuel, Ramos Natalia, Azancot María A, Rodríguez-Frías Francisco, Buti Maria

Abstract excerpt

BACKGROUND AND AIM: Patients with chronic kidney disease (CKD) and hepatitis C infection can be safely and effectively treated with direct-acting antivirals (DAAs). However, there is scarce data on the long-term impact of hepatitis C cure on CKD. The aim of this study was to assess the long-term mortality, morbidity and hepatic/renal function outcomes in a cohort of HCV-infected individuals with CKD treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Follow-Up Studies

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Kidney Failure, Chronic

Share to Renal Insufficiency, Chronic

Source

Open in PubMed

Identifiers

PMID: 36584754
DOI: 10.1016/j.gastrohep.2022.12.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.PMID 36584754Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Semantic proximity Read ↗

Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Semantic proximity Read ↗

Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.Semantic proximity Read ↗

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.Semantic proximity Read ↗

Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.Semantic proximity Read ↗

KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.Semantic proximity Read ↗

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Semantic proximity Read ↗

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.